Article
Imatinib for systemic mast-cell disease.
Lancet (London, England) - 16 Aug 2003
Pardanani A, Elliott M, Reeder T, Li C Y, Baxter E J, Cross N C P, Tefferi A
Abstract excerpt
Imatinib has shown to be effective against malignant disease driven by ckit. We prospectively treated 12 adults with symptomatic systemic mast-cell disease at a dose of either 100 mg or 400 mg per day. Of the ten patients who we could assess for response, five (50%) had a measurable response to the drug, four of whom had important mast-cell cytoreduction and two who had complete clinical and histological...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.